Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy

摘要

Breast cancer is not pink ribbons and easy decision making. Worldwide, premenopausal women accounted for just over 30% of global breast cancer diagnoses in 2018 and nearly all global regions demonstrate increasing rates of breast cancer in this population.1 Although biology may be at play for poorer outcomes, we also note that premenopausal women, particularly the very young (< 40 years of age), have been shown to have higher rates of endocrine therapy non-adherence (40% more likely) or early discontinuation (50% more likely) than those persons age 50-65 years, likely because of side effects and negative impact on overall quality of life.2 Enter the modern age, where we look back to move forward: sifting through the data from the 8-year combined analysis of the SOFT/TEXT trials,3 which accrued patients from 2003 to 2011, and the TailorX trial,4 which accrued patients from 2006 to 2010, to inform practice in 2021. But during those time intervals, practice advanced in many ways, including the contemporary impact of both trials on the other.